What management steps should a patient with type 1 diabetes follow when they develop a viral infection such as COVID‑19?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 27, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Management of Type 1 Diabetes During Viral Infections Including COVID-19

Patients with type 1 diabetes who develop a viral infection such as COVID-19 must never stop insulin therapy, implement intensive glucose monitoring every 2-4 hours, follow sick day rules, and maintain heightened vigilance for diabetic ketoacidosis (DKA), which occurs with increased frequency during these infections. 1

Critical Insulin Management

Insulin therapy is non-negotiable and must be continued throughout any viral illness. 1 The evidence demonstrates that:

  • Patients with type 1 diabetes experience disproportionately high insulin resistance during COVID-19 infection, requiring substantially higher insulin doses than typically seen with other critical illnesses 1
  • Blood glucose monitoring must intensify to every 2-4 hours, or continuous glucose monitoring should be utilized 1
  • Insulin doses require careful adjustment based on frequent glucose readings, diabetes type, comorbidities, and clinical status 1

DKA Prevention: The Primary Threat

The most critical complication in type 1 diabetes patients with viral infections is DKA, which has shown increased prevalence during COVID-19. 1 This heightened risk stems from:

  • Elevated HbA1c compromising immune function and rendering patients more susceptible to metabolic decompensation 1
  • Delayed hospital admission contributing to severe DKA presentations 1
  • Potential direct beta-cell damage from viral infection leading to insulin deficiency 1

Specific DKA Monitoring Protocol

Patients must be re-educated on:

  • Typical DKA symptoms recognition
  • Home measurement of urine or blood ketones
  • Acute behavior guidelines during illness
  • Liberal and early contact with medical professionals when symptoms develop 1

Medication Adjustments for Type 1 Diabetes Patients

SGLT-2 Inhibitors (if prescribed off-label)

Stop immediately during any viral illness. 1 These medications (canagliflozin, dapagliflozin, empagliflozin) carry significant risks during infection:

  • Dehydration risk
  • Euglycemic or moderate hyperglycemic DKA
  • Acute kidney injury
  • Should not be initiated during respiratory illness 1

Recent evidence confirms SGLT-2 inhibitors are contraindicated in certain COVID-19 conditions, with insulin recommended as first-line treatment for acute glycemic control 2, 3

GLP-1 Receptor Agonists (if prescribed)

Continue with caution and intensive hydration monitoring. 1 For medications like dulaglutide, liraglutide, or semaglutide:

  • Dehydration can rapidly progress to serious illness
  • Adequate fluid intake must be encouraged
  • Regular meals should be maintained when possible 1

Sick Day Rules Implementation

Follow structured sick day protocols rigorously: 1

  • Monitor renal function carefully due to high risk of acute kidney injury or chronic kidney disease progression 1
  • Maintain hydration aggressively
  • Continue insulin with dose adjustments based on frequent glucose monitoring
  • Check ketones regularly (urine or blood)
  • Seek medical attention early if glucose remains elevated despite insulin adjustments or ketones are present

Telemedicine and Remote Monitoring

Utilize connected health models and telemedicine for ongoing diabetes management during viral illness. 1 This approach:

  • Reduces exposure risk while maintaining care continuity
  • Enables virtual self-management education
  • Ensures medication adherence monitoring
  • Facilitates early intervention before complications develop 1

Evidence from the pandemic demonstrates that telemedicine accompanied by diabetes technology data allows effective remote care delivery, though pre-existing disparities in technology access persist 4

Risk Stratification

Specific risk factors predict worse outcomes in type 1 diabetes patients with COVID-19: 4, 5

  • Higher HbA1c levels (positively associated with hospitalization, OR 1.42,95% CI 1.18-1.76) 5
  • Older age
  • Lack of continuous glucose monitoring use
  • Non-use of insulin pumps
  • Presence of hypertension 5

Common Pitfalls to Avoid

  1. Never discontinue insulin even if oral intake is poor—adjust doses but maintain basal coverage 1
  2. Do not wait for severe symptoms before checking ketones or seeking medical advice 1
  3. Avoid prophylactic medication discontinuation in asymptomatic patients—only stop SGLT-2 inhibitors when illness is present 1
  4. Do not underestimate insulin requirements—COVID-19 causes disproportionate insulin resistance requiring aggressive dose escalation 1

Glycemic Targets During Illness

While maintaining glucose control is essential to reduce infection severity risk, the primary focus shifts to preventing DKA and severe hyperglycemia rather than achieving tight control. Accept slightly higher glucose targets (avoiding hypoglycemia) while ensuring ketones remain negative and insulin is never withheld.

References

4
Research

Type 1 and Covid-19: Diagnosis, Clinical Care, and Health Outcomes during the Pandemic.

Endocrinology and metabolism clinics of North America, 2024

Related Questions

Should the dose of Lantus (insulin glargine) be reduced when a patient with diabetes is sick with an upper respiratory infection?
How should I manage a persistent three‑week cough in a 42‑year‑old man with type 2 diabetes mellitus on insulin, end‑stage renal disease on dialysis, hypertension, and current medications (insulin, rosuvastatin, vildagliptin, atenolol, losartan, sertraline, calcium supplements, and furosemide), who also has mild watery rhinorrhea and occasional sneezing after a resolved viral upper respiratory infection?
What is the appropriate management for a diabetic patient with an upper respiratory tract infection?
What blood tests are recommended to evaluate for Alzheimer’s disease or risk of dementia?
What duration of close exposure to a person with active pulmonary tuberculosis is needed for infection?
Is it appropriate to decrease olanzapine to 7.5 mg daily and add escitalopram, and what dosing and monitoring steps should be followed?
What conditions are low vitamin D levels associated with?
How should an acute facial rash with burning and peeling that develops during an ear infection be evaluated and managed?
What is the recommended treatment for a patient who develops facial and neck erythema, pruritus, burning, and desquamation following a Group A streptococcal infection?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.